Although pregnancy may conceal breast cancer in younger women, survival statistics are similar.
Although pregnancy may conceal breast cancer in younger women and lead to a delay in diagnosis, evaluation, and treatment, pregnancy-associated breast cancers are not associated with a worse outcome compared to nonpregnancy-associated breast cancers, according to research published online Feb. 9 in Cancer.
Beth M. Beadle, MD, PhD, of The University of Texas M.D. Anderson Cancer Center in Houston, and colleagues retrospectively reviewed breast cancer-related outcomes among women with pregnancy- and non-pregnancy-associated malignancies. A total of 652 women (aged 35 years or younger) were included, with a median follow-up of 114 months.
Compared to women with nonpregnancy-associated breast cancers, women with pregnancy-associated tumors did not significantly differ in their 10-year rates of locoregional recurrence (23.4% for women with pregnancy-associated tumors vs. 19.2% for women with nonpregnancy-associated tumors), distant metastases (45.1% vs. 38.9%) and overall survival (64.6% vs. 64.8%), the researchers report. In pregnant women, any treatment intervention taken during pregnancy improved the trend for overall survival compared with delaying treatment until after delivery, the authors note.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More